IL10 and neoplasm: The injection of iNKT cell agonists into mice with tumors led to a significant reduction in the frequency of MDSCs and the removal of the immunosuppressive factor IL-10 from MDSCs, leading to an increase in the frequency of tumor-specific T cells as well as inhibiting tumor progression [93].